跳到正文
MHRA Inspectorate· Chris Jones·精选AI 评分60

MHRA 博客称将不再例行联系持证方,要求自行审查 USFDA 警告信

FDA Warning Letters

AI 导读

英国 MHRA 表示将调整对 USFDA 警告信的处理方式,今后不再例行联系可能受影响的持证方,要求生产和批发许可持有人及 API 注册持有人自行审查并风险评估这些警告信。MHRA 指出 USFDA 警告信属非正式且建议性的公开信息,涉及缺陷药品可通报 DMRC,涉及持续合规可通报 IAG。

推荐理由

MHRA 说明今后不再例行联系持证方,转而要求其自行审查并评估 USFDA 警告信,可帮助了解这一监管衔接安排的调整。

正文 · 原文

This Blog relates to actions which licence holders should do following the issuing of USFDA Warning Letters. 

The MHRA’s Inspection Action Groups (IAG) are responsible for recommending and implementing regulatory action against companies for breaches across all GxPs, and its Defective Medicines Report Centre (DMRC) provides an emergency assessment and communication system for manufacturers and regulatory authorities in regard to defective medicines. Click to find more information about the important roles that are performed by the IAG and DMRC.

The IAG and DMRC regularly receives USFDA Warning Letters (also Official Action Indicated, OAI, and Import Ban letters) and contacts UK licence holders who may be implicated – e.g. in instances where a company in receipt of a letter may be a contract manufacturer or API supplier for a company who has medicines marketed in the UK.

The MHRA has reviewed its current approach. IAG and DMRC note that these letters are in the public domain and takes the view all manufacturing and wholesale licence holders, as well as API (Active pharmaceutical ingredient) registration holders should be reviewing these warning letters as part of their ongoing quality assessment of suppliers and contract manufacturers. While technical agreements between third party suppliers should be sufficiently robust to ensure these are provided as a matter of course, IAG and DMRC regards it to be prudent to check as part of routine qualification and re-qualification activities.

In future, MHRA will not be contacting licence holders as a matter of routine and companies should ensure they have measures in place to review and risk assess USFDA Warning Letters. Should this risk assessment require notification to MHRA then this could be via the DMRC (if medicines are defective) and to IAG (in regard to ongoing regulatory compliance). 

The USFDA warning letters are informal and advisory. They are not an indication that action is going to be taken. The company in question can respond to the letter, the USFDA will review the response and may re-inspect or take other actions.

See the FDA Warning Letters.

Contact

DMRC@mhra.gov.uk

IAGSecretariat@mhra.gov.uk

来源:MHRA Inspectorate · mhrainspectorate.blog.gov.uk